Clinical Trials
26 trialsNCT05520099 2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT06926075 2026-03-17
ADVICE
Filamon LTD
Phase 1/2 Recruiting
NCT07327489 2026-01-08
ELEPHAS-05
Elephas
Recruiting
NCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT03452774 2025-10-28
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Recruiting
NCT04825834 2025-08-08
DELFI-L101
Delfi Diagnostics Inc.
Completed
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT04774952 2025-04-15
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Completed
NCT04929912 2025-01-29
PIONEER
Mirai Medical
Recruiting
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT06583395 2024-11-01
QUANTUM
VitaMed Research LLC
Enrolling by invitation
NCT01931644 2024-04-18
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
Completed
NCT03602079 2023-08-03
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase 1/2 Completed
NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
NCT04311710 2023-02-24
CheckMate 76U
Bristol-Myers Squibb
Phase 1 Terminated
NCT03634982 2022-09-01
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Unknown
NCT03896958 2020-12-04
PIONEER
SpeciCare
Unknown
NCT00333502 2020-05-28
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Lumos Pharma
Phase 1/2 Completed
NCT02602067 2018-09-18
Tenatumomab
sigma-tau i.f.r. S.p.A.
Phase 1 Terminated
NCT02262455 2017-02-13
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
Phase 1 Completed
NCT01300533 2016-02-09
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
BIND Therapeutics
Phase 1 Completed
NCT00689065 2013-11-01
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Calando Pharmaceuticals
Phase 1 Terminated
NCT00094003 2005-11-11
Study of NS-9 in Patients With Liver Metastases
NS Pharma, Inc.
Phase 1 Completed